Learn About Acute Hepatic Porphyria (AHP)

What is the definition of Acute Hepatic Porphyria (AHP)?
Acute hepatic porphyria is a genetic metabolic disorder caused by a defect in the enzyme that assists heme synthesis, which results in the accumulation of porphyrins. Heme is involved in the production of hemoglobin, or the oxygen-carrying element in the blood, and porphyrins are molecules that help produce heme. There are several types of hepatic porphyria, including acute intermittent porphyria, variegate porphyria, aminolevulinic acid dehydratase deficiency porphyria, hereditary coproporphyria, and porphyria cutanea tarda.
Save information for later
Sign Up
What are the symptoms of Acute Hepatic Porphyria (AHP)?
Symptoms of acute hepatic porphyria may include severe abdominal, chest, arm, leg, and back pain; nausea; vomiting; constipation; rapid heartbeat; high blood pressure; muscle weakness; sensory loss; multiple nerve pain; blistering rashes; excessive hair loss; dark or reddish-brown urine; low blood sodium levels; seizures; and psychosis.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Acute Hepatic Porphyria (AHP)?
Treatment for acute hepatic porphyria includes the administration of pain medication and intravenous hemin; carbohydrate loading; intravenous hypertonic saline; seizure control with benzodiazepine, gabapentin, Propofol, or magnesium; and liver transplantation.
Who are the top Acute Hepatic Porphyria (AHP) Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Acute Hepatic Porphyria (AHP) Clinical Trials?
Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture
Summary: To determine the proportion of patients suffering from acute hepatic porphyria (AHP) from different hospital departments and referred to an internist referent for a suggestive clinical picture with a first negative etiological assessment.
Match to trials
Find the right clinical trials for you in under a minute
Get started
Estimating the Frequency and Neuro-Hormonal Characteristics of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Summary: Postural Tachycardia Syndrome (POTS) is the most common autonomic disorder and is estimated to affect 3,000,000 individuals in the United States, with 80-85% of patients being women. The condition is characterized by a rapid increase in heart rate (HR) that occurs on standing, and chronic symptoms of cerebral hypoperfusion leading to lightheadedness, dizziness, and blurred vision.~The acute hepati...
What are the Latest Advances for Acute Hepatic Porphyria (AHP)?
New therapeutic option for acute hepatic porphyrias.
Summary: New therapeutic option for acute hepatic porphyrias.
Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Summary: Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Tired of the same old research?
Check Latest Advances
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Summary: Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.